Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
J Card Fail
25% of patients were followed for 6.1 years or longer
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: The LixiLan proof-of-Concept randomized trial
95% CI, 2.743.99), whereas no significant difference in urinary tract infections was seen between SGLT2is versus control (RR, 1.05
Ultimately, exendin-4 may play role as a novel treatment of NAFLD via direct effect on hepatic lipid and glucose metabolism
US$ 20.33
US$ 22.08
US$ 23.43
US$ 21.49
US$ 20.69
US$ 21.60
US$ 20.58
US$ 21.44
